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A B S T R A C T
Background
Interferon-c receptor 1 (IFN-cR1) deficiency is a life-threatening inherited disorder, conferring
predisposition to mycobacterial diseases. Haematopoietic stem cell transplantation (HSCT) is
the only curative treatment available, but is hampered by a very high rate of graft rejection,
even with intra-familial HLA-identical transplants. This high rejection rate is not seen in any
other congenital disorders and remains unexplained. We studied the underlying mechanism in
a mouse model of HSCT for IFN-cR1 deficiency.
Methods and Findings
We demonstrated that HSCT with cells from a syngenic C57BL/6 Ifngr1þ/þ donor engrafted
well and restored anti-mycobacterial immunity in naive, non-infected C57BL/6 Ifngr1/
recipients. However, Ifngr1/ mice previously infected with Mycobacterium bovis bacillus
Calmette-Gue´rin (BCG) rejected HSCT. Like infected IFN-cR1-deficient humans, infected Ifngr1/
mice displayed very high serum IFN-c levels before HSCT. The administration of a recombinant
IFN-c-expressing AAV vector to Ifngr1/ naive recipients also resulted in HSCT graft rejection.
Transplantation was successful in Ifngr1/ 3 Ifng/ double-mutant mice, even after BCG
infection. Finally, efficient antibody-mediated IFN-c depletion in infected Ifngr1/mice in vivo
allowed subsequent engraftment.
Conclusions
High serum IFN-c concentration is both necessary and sufficient for graft rejection in IFN-cR1-
deficient mice, inhibiting the development of heterologous, IFN-cR1-expressing, haemato-
poietic cell lineages. These results confirm that IFN-c is an anti-haematopoietic cytokine in vivo.
They also pave the way for HSCT management in IFN-cR1-deficient patients through IFN-c
depletion from the blood. They further raise the possibility that depleting IFN-c may improve
engraftment in other settings, such as HSCT from a haplo-identical or unrelated donor.
The Editors’ Summary of this article follows the references.
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Introduction
Complete deﬁciency of the ligand-binding chain of the
interferon-c receptor (IFN-cR1) is an autosomal recessive
disorder described in 1996 as the ﬁrst genetic aetiology of the
syndrome of Mendelian Susceptibility to Mycobacterial
Diseases (‘‘MSMD’’: MIM 209950) [1–3]. Causal mutations
either abrogate cell surface IFN-cR1 expression [4,5] or
prevent IFN-c recognition due to the production of surface-
expressed, non-functional receptors [6]. Both types of IFN-
cR1 deﬁciency result in a complete loss of cellular responses
to IFN-c. This disorder confers a profound and selective
susceptibility to weakly virulent mycobacteria, such as
Mycobacterium bovis bacillus Calmette Gue´rin (BCG) vaccines
and environmental mycobacteria [7], as reviewed in [3].
Humans are also susceptible to the more virulent M.
tuberculosis [7,8]. Other infectious diseases are rare, with the
exception of salmonellosis, which has been diagnosed in
several patients [9]. Listeriosis and a few viral diseases were
each diagnosed in single patients [7,10]. Humans do not
produce mature granulomas in response to mycobacteria,
and instead display poorly delimited, poorly differentiated,
multibacillary tissue lesions [11]. They present with early-
onset, disseminated, recurrent, and multiple mycobacterial
infections. Most patients die in early childhood, with only
one-third surviving to the age of 15 years [7].
The treatment of patients with complete IFN-cR1 deﬁ-
ciency is particularly difﬁcult [3,7]. Antibiotics alone do not
achieve permanent clinical remission. Unlike patients with
other MSMD aetiologies, those with complete IFN-cR1 (or
IFN-cR2) deﬁciency do not beneﬁt from exogenous IFN-c
administration, owing to the lack of a speciﬁc receptor. The
remission of mycobacterial infection following the ﬁrst case
of haematopoietic stem cell transplantation (HSCT) in such
an individual provided proof-of-principle that IFN-cR1
deﬁciency is primarily a haematopoietic disorder, despite
the ubiquitous expression of IFN-cR1 [12]. However, sub-
sequent attempts revealed a very high rate of primary and
secondary rejection in HLA-identical HSCT [13–15]. Nine
patients received a total of 12 transplants. Four of these
patients died within eight months of transplantation—from
mycobacterial disease in two cases—and three individuals
rejected the graft. Two of the ﬁve patients who survived
presented only very low levels of chimerism and no
chimerism was observed in a third. One individual had a
low-grade infection at the time of the treatment [15]. Only
three individuals have remained free from infectious com-
plications [13,15] and are currently healthy, nine, seven, and
seven years after HSCT. This rate of HLA-identical graft
rejection is by far the highest reported for HSCT to treat
primary immunodeﬁciencies or congenital disorders [16].
These observations indicate that HSCT is potentially curative
in IFN-cR1-deﬁcient individuals, but associated with a
particularly high and unexplained rate of graft rejection,
resulting in unacceptable morbidity and mortality rates.
We used mice selectively deﬁcient in IFN-c R1 (Ifngr1/),
IFN-c (Ifng/), or both (Ifngr1/3 Ifng/) [17,18], as a means
of investigating the mechanism of graft rejection in IFN-cR1-
deﬁcient patients. These mice are susceptible to several
intracellular pathogens [17,19–23]. In particular, Ifngr1/
mice are highly susceptible to mycobacteria, such as M.
tuberculosis [24,25], M. avium [26] and BCG [27]. Ifngr1/ mice
die within nine weeks of the intravenous injection of 23 107
cells of BCG, whereas control mice survive such injections
[27]. BCG is also the most common pathogen in IFN-cR1-
deﬁcient individuals [7]. On histological examination, these
patients have tissue lesions containing large numbers of acid-
fast BCG, with small numbers of structurally impaired
granulomas and high tissue loads of mycobacteria [4,11].
The same infectious phenotype has been observed in Ifng/
mice infected with BCG [18]. Thus, the extreme susceptibility
of Ifngr1/ mice to mycobacterial infections, including BCG
in particular, mimics the human condition, making these
mice an ideal model for studies of the mechanisms underlying
the HSCT failure observed in IFN-cR1-deﬁcient humans.
Materials and Methods
Animals
Speciﬁc pathogen-free, Ifngr1þ/þ C57BL/6 mice were pur-
chased from Charles River (L’Arbresle, France) and used at
six to nine weeks of age. Interferon gamma receptor chain 1
(Ifngr1/, stock no. 003288, N10) [17] and interferon gamma
(Ifng/, stock no. 002287, N10) [18] mice were purchased from
JaxLab and reared at the CDTA (Centre de Distribution,
Typage et Archivage animal, Orle´ans, France). Both Ifngr1/
and Ifng/ mice were backcrossed onto the C57BL/6 back-
ground for more than ten generations. Double knock-out
(DKO) mice (Ifngr1/3 Ifng/) were generated in a pathogen-
free animal facility, by mating homozygous Ifng/ mice with
Ifngr1/ mice. The resulting F1 animals were then inter-
crossed to generate double homozygous mice, identiﬁed by
PCR on tail DNA (primers and conditions available from the
JaxLab Web site [http://jaxmice.jax.org/strain/002287.html and
http://jaxmice.jax.org/strain/003288.html]). All experiments
and procedures were performed in accordance with French
Ministry of Agriculture regulations for animal experimenta-
tion (1987) and the guidelines of our institution’s animal
welfare committee.
Haematopoietic Stem Cell Transfer
Recipient mice were subjected to intensive or milder doses
(550 rads to 1,200 rads) of body irradiation, using a Cs137
radioactive source (Pasteur Institute). Immune reconstitution
was then initiated by the intravenous administration, via a
lateral tail vein, of two million total bone marrow cells freshly
isolated from donor mice. Brieﬂy, bone marrow cells were
ﬂushed into PBS from the femurs and tibias of donor mice.
Red blood cells were lysed and the remaining cells were
counted before bone marrow cell transfer. After engraftment,
mice were kept in a speciﬁc-pathogen-free animal facility, in
ﬁlter-topped cages in an isolation room. All caging proce-
dures and manipulations were carried out in a laminar ﬂow
hood. Mice were used for experimental infection eight weeks
after HSCT.
Analysis of Chimerism and Reconstitution
The extent of haematopoietic reconstitution by the donor
phenotype was assessed every two weeks, during the eight
weeks before experimental infection, using speciﬁc anti-
bodies. Immunoﬂuorescence analyses were carried out on
whole blood. Brieﬂy, donor bone marrow cells expressed the
Ly5.1 marker, whereas recipient leukocytes expressed the
Ly5.2 marker. Chimerism was therefore assessed as the
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percentage of cells expressing the Ly5.1 isotype (engraft-
ment). Antibodies against the following surface antigens (all
from BD Bioscience Pharmingen) were used, as FITC or PE
conjugates, to evaluate peripheral reconstitution: TCRab,
B220, Mac-1 and GR1. Blood (25 ll) was ﬁrst blocked with
24G2 serum, then stained with speciﬁc antibodies. Red blood
cells were then lysed with PharM Lyse buffer and ﬂow
cytometry was carried out on the remaining cells (FACScan,
Becton Dickinson).
Experimental Infection with BCG and Determination of
the Number of Colony-Forming Units
BCG strain Pasteur 1173P2 was used [28]. BCG was
prepared as described elsewhere [29], frozen in aliquots and
stored at 80 8C. For each infection experiment, groups of
non-irradiated animals were included as positive and
negative controls of infection. Bacteria were counted in the
spleen and liver, as described elsewhere [29]. In brief, blood
samples were taken from six to eight mice for each point. The
mice were then killed, and their organs were dissected out,
placed in 2 ml screw-cap tubes ﬁlled with sterile water and
homogenized with a 5 mm stainless steel ball (SKF) using a
mini-8 bead-beater (Biospec). Spots (50 ll) of serial ﬁve-fold
dilutions of this suspension were plated on Middlebrook
7H11 medium supplemented with OADC (Difco). The plates
were incubated for 20 d at 37 8C, under a humidiﬁed
atmosphere containing 5% CO2, and colonies were counted
using a stereoscopic binocular microscope with a detection
threshold of 170 CFU per organ.
ELISA
Serum was recovered from whole blood samples following
coagulation. Serum aliquots were frozen at 20 8C for
quantitative sandwich immunoassays for IFN-c. Mouse ELISA
kits from R&D Systems were used, according to the
manufacturer’s recommendations, in all experiments. The
detection limit of the kit was less than 2 pg/ml.
RNA Purification and Northern Blot Analysis
Tissue samples were lysed in 1 ml of Trizol (Invitrogen) and
the resulting suspensions were immediately frozen and stored
at 80 8C. Total RNA was extracted with a kit based on the
acid phenol-guanidine method, according to the manufac-
turer’s instructions. Total RNA concentration was estimated
by spectrophotometry. Total RNA (15 lg in 50% formamide)
was blotted onto a nylon membrane. The membrane was
incubated for three hours at 80 8C and was then washed in
23SSC before hybridisation with murine IFN-c and GAPDH
probes generated by PCR (primers available on request) and
labelled with 32P by random priming. Each autoradiograph
was densitometrically scanned and levels of the speciﬁc IFN-c
transcripts were normalised with respect to GAPDH tran-
script levels.
Preparation and Use of Recombinant Adeno-Associated
Vectors and Injection
The mouse IFN-c cDNA was ampliﬁed by PCR from the
L929 cell line and inserted into convenient restriction sites in
the pGG1 vector. The resulting plasmid was sequenced to
check the integrity of the mIFN-c cDNA. We prepared rAAV-
IFN-c particles, as previously described [30], by a helper-
virus-free method involving the triple transfection of HEK
293 cells. Physical particles were estimated by dot plots, and
1.73 1012 such particles were obtained per ml of preparation
[31]. We assessed rAAV-IFN-c particle function in vivo, by
injecting 53 1010 rAAV particles, in a ﬁnal volume of 100 ll,
into the left gastrocnemius muscle of recipient Ifngr1/mice.
Serum samples were recovered at various time points after
injection and mIFN-c was quantiﬁed by ELISA. A rAAV
vector including the lacZ gene was used as negative control.
Antibody-Mediated Cytokine Neutralisation
Animals were infected with 106 CFU of BCG. Fourteen days
later, they received an intraperitoneal injection of a mixture
of 0.8 mg of puriﬁed rat anti-mouse IFN-c antibody (clone
XMG1 [32]) and 0.8 mg of puriﬁed rat anti-mouse IL-12p40
antibody (clone C15–1 [33]). Antibodies were puriﬁed from
the culture supernatant by ammonium sulphate precipitation
and shown to function effectively in a mouse model of
Plasmodium infection [34]. The control group received an
injection of 1.6 mg of irrelevant puriﬁed rat IgG antibody
(Sigma). In all groups, the injection was repeated on days 15,
17, 20, and 24. Bone marrow from Ifngr1þ/þ donors was
transferred to the recipient mice 23 d after sublethal body
irradiation (550 rad). Serum IFN-c concentration and
chimerism were monitored throughout the experiment.
Histology
Organs were ﬁxed by immersion for 24 h in 3.7%
formaldehyde and were then transferred to 70% ethanol
for 24 h to 48 h before embedding in parafﬁn. Sections (5 lm)
were cut on a rotary microtome, stretched in a water bath,
mounted on glass slides and stained with haematoxylin-eosin-
saffron (HES) or by the Zielh-Neelsen method.
Results
Ifngr1/ Mice Are Susceptible to BCG Infection
C57BL/6 Ifngr1/ mice were unable to control BCG
infection following intravenous injection with  102 CFU
(Figure 1A). Deﬁcient animals survived 29 6 2 weeks (mean 6
SD) following challenge with 102 CFU, whereas no mortality
was observed in wild-type C57BL/6 control mice (Ifngr1þ/þ)
during 12 mo of follow-up, even after infection with the
highest counts of CFU. The survival of deﬁcient animals was
inversely proportional to the size of the inoculum (Figure
1A), with mortality ranging from 29 wk with 102 CFU to 12 wk
with 106 CFU. Ifngr1/ mice challenged i.v. with 106 CFU of
BCG were unable to control the infection: the bacterial load
in the spleen increased to 7.4 6 0.3 (Log10 CFU) by 45 d after
infection and exceeded 8 Log10 CFU in dying animals (Figure
1B). In Ifngr1þ/þmice, the BCG burden was controlled, with a
decrease in CFU observed by day 45, and CFU numbers
falling to 5 Log10 by day 90. Granuloma formation was altered
in BCG-infected Ifngr1/ mice. Two weeks after infection,
Ifngr1/ mice had fewer and smaller granulomas in both the
spleen and the liver than infected Ifngr1þ/þ control mice.
Granulomas were mostly lymphoid, with no recruitment of
epithelioid cells, whereas the granulomas observed in Ifngr1þ/þ
BCG-infected mice contained mostly epithelioid cells and a
few lymphocytes (unpublished data). By day 90 post-infection,
Ifngr1/mice presented massive mycobacterial dissemination
associated with large necrotising granulomas. In contrast, a
very small number of small, well-delimited granulomas were
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observed in infected Ifngr1þ/þ control mice (unpublished
data). These data are consistent with the absence of mature
granulomas observed in patients entirely lacking IFN-cR1
[11]. Our results conﬁrm that Ifngr1/ mice are highly
susceptible to M. bovis BCG infection, consistent with
previous reports [27], and validate this model for the study
of IFN-cR1 deﬁciency in humans.
HSCT Restores Anti-Mycobacterial Immunity in Ifngr1/
Mice
We subjected C57BL/6 Ifngr1/mice to HSCT with sex- and
age-matched syngenic C57BL/6 Ifngr1þ/þ donors with an
intensive total body irradiation conditioning regimen (1,200
rad). Several doses of bone marrow were tested and we found
that 2 million cells was the dose most comparable to HSCT in
humans. Leukocyte chimerism was complete, with low levels
of residual autologous cells nine wk after treatment.
Peripheral reconstitution was achieved, with the expected
counts of lymphoid (T and B) and myeloid (macrophages and
granulocytes) cells (Figure 2A, unpublished data). We then
evaluated the ability of the recipient mice to control BCG
infection. Ten weeks after HSCT, animals were challenged i.v.
with 106 CFU of BCG. They were killed 45 d later and BCG
load in the spleen was determined. Ifngr1/ animals trans-
planted with Ifngr1/ bone marrow were unable to control
BCG infection, like Ifngr1þ/þ animals receiving Ifngr1/ bone
marrow (Figure 2B). Ifngr1/ animals receiving Ifngr1þ/þ bone
marrow controlled the infection as efﬁciently as Ifngr1þ/þmice
receiving Ifngr1þ/þ bone marrow or mice with no graft (Figure
2B). HSCT recipients conditioned with a milder regimen (550
rads) displayed mixed chimerism, with only about 50% donor
Ly5.1 lymphocytes (Figure 2C). The donor haematopoietic
compartment had nonetheless restored BCG growth control
45 d after infection (Figure 2D). Thus, the restoration of IFN-
cR1 expression in the haematopoietic compartment alone,
even in only a fraction of the compartment, is sufﬁcient to
confer resistance to BCG infection. Mycobacterial disease in
mice with IFN-cR1 deﬁciency therefore results from the
speciﬁc absence of IFN-cR1 in the haematopoietic compart-
ment, consistent with reported data for HSCT in human
patients [12,13].
Rejection of HSCT in Ifngr1/ Mice Previously Infected
with BCG
All the IFN-cR1-deﬁcient patients undergoing HSCT had a
history of mycobacterial disease, as HSCT has not yet been
attempted in an asymptomatic child [12–15]. We thus
infected animals with BCG before HSCT. Ifngr1/ and
Ifngr1þ/þ mice were infected intravenously with 106 CFU
BCG and subjected to HSCT 40 d later, with sex- and age-
matched syngenic Ifngr1þ/þ donors. Following intense irradi-
ation (1,200 rads), both Ifngr1/ and Ifngr1þ/þ BCG-infected
mice displayed successful immune reconstitution with
Ifngr1þ/þ bone marrow (unpublished data). However, with a
milder conditioning regimen (550 rads) more closely mimick-
ing the situation in human transplant patients in terms of the
chimerism post HSCT [12–15], Ifngr1/ mice infected with
BCG before HSCT rejected the graft, with Ly5.1 lymphocytes
from the donor phenotype accounting for less than 2% of the
circulating cells, whereas about 50% chimerism was observed
in the absence of BCG infection (Figure 3A). Serving as a
control, Ifngr1þ/þ mice infected with BCG and subjected to
HSCT with Ifngr1þ/þ donor marrow, under the same milder
conditioning regimen, displayed successful engraftment and
reconstitution. Bacterial loads, determined 11 wk after
infection, reached 8.4 Log10 CFU per spleen in the Ifngr1
/
cohort, versus only 4.5 Log10 CFU in Ifngr1
þ/þ mice (Figure
3B). Histological observations conﬁrmed dissemination in the
Ifngr1/ cohort, contrasting with small, well-delimited gran-
ulomas in Ifngr1þ/þ animals (unpublished data). Thus, Ifngr1/
mice infected with BCG reject HSCT, with features mimick-
ing the graft rejection observed in IFN-cR1-deﬁcient patients.
HSCT Graft Rejection Is Associated with High Serum IFN-c
Levels
High serum IFN-c concentration is a hallmark of human
complete IFN-cR1 deﬁciency [35]. We thus monitored serum
IFN-c levels in BCG-infected Ifngr1/ and Ifngr1þ/þmice. IFN-
c was detected as early as 10 d post-infection and its
concentration gradually increased towards a plateau at about
6 ng/ml within six wk of infection in Ifngr1/mice, conﬁrming
Figure 1. Ifngr1/ Mice Are Susceptible to BCG Infection
(A) Ifngr1/ mice were infected with between 102 and 106 CFU of BCG,
and animal survival (five animals per group) was monitored thereafter.
(B) Splenic mycobacterial loads were determined on days 4, 15, 45, and
90 in infected Ifngr1/ and Ifngrþ/þmice; means of five animals per point
are shown.
doi:10.1371/journal.pmed.0050026.g001
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previous observations [36]. IFN-c remained barely detectable
in infected Ifngr1þ/þ mice (Figure 4A). Serum IFN-c levels,
determined 30 d after BCG infection in Ifngr1/ and Ifngr1þ/þ
mice previously subjected to HSCT, were found to correlate
with the control of BCG infection. IFN-c levels were high in
Ifngr1/ animals engrafted with Ifngr1/ bone marrow and
only marginally elevated in Ifngr1þ/þ animals engrafted with
Ifngr1/ bone marrow (Figure 4B). In these conditions IFN-c
levels were very similar to those in BCG-infected non-
transplanted Ifngr1/ mice (Figure 4A). IFN-c was almost
undetectable in both Ifngr1/ mice engrafted with Ifngr1þ/þ
bone marrow and Ifngr1þ/þmice engrafted with Ifngr1þ/þ bone
marrow, as for non-transplanted Ifngr1þ/þ animals (Figure 4B).
Following HSCT with mild conditioning after M. bovis BCG
infection, IFN-c concentration seemed to be high only in the
cohort of Ifngr1/ animals infected at the time of cell
transfer, and in such cases, HSCT was unsuccessful (Figures
3A and 4C). These results were conﬁrmed by quantiﬁcation of
IFN-c transcripts in the spleens of infected animals. Infected
Ifngr1/mice contained signiﬁcantly larger amounts of IFN-c
Figure 2. HSCT Restores Anti-Mycobacterial Immunity in Ifngr1/ Mice
(A) Ifngr1/ and Ifngrþ/þ mice (five animals per group) expressing the Ly5.2 marker were subjected to HSCT with bone marrow from Ifngrþ/þ mice
expressing the Ly5.1 marker, after intense irradiation (1,200 rads). Chimerism, assessed by determining the surface expression of Ly5.1 and Ly5.2 on
lymphocytes, and peripheral reconstitution, assessed by determining the surface expression of TCRab and B220 markers on lymphocytes, were analysed
by flow cytometry nine weeks after HSCT treatment.
(B) Ifngr1/ and Ifngrþ/þmice were subjected to HSCT with bone marrow from Ifngr1/ or Ifngrþ/þmice. HSCT-treated mice were then infected with BCG
and bacterial loads were determined 45 d later (five animals per group).
(C) Ifngr1/ and Ifngrþ/þmice expressing the Ly5.2 marker were subjected to HSCT with bone marrow from Ifngrþ/þmice expressing the Ly5.1 marker,
after mild irradiation (550 rads). Chimerism and peripheral reconstitution were analysed by flow cytometry nine weeks after HSCT treatment.
(D) Ifngr1/ and Ifngrþ/þ mice were subjected to HSCT with bone marrow from Ifngrþ/þ mice after intense or mild irradiation, infected with BCG and
bacterial load was determined 45 d later.
doi:10.1371/journal.pmed.0050026.g002
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mRNA than infected Ifngr1þ/þ animals (Figure 4D). Basal levels
of IFN-c were detected in non-infected Ifngr1/ and Ifngr1þ/þ
mice. As expected, no IFN-c mRNA was detected in Ifng/
mice. The amounts of IFN-c mRNA in infected Ifngr1/ and
Ifngr1þ/þ mice differed by a factor of 2.25 (p  0.007). Thus,
serum IFN-c concentration increased with BCG infection and
was inversely correlated with HSCT engraftment in the
murine model of IFN-cR1 deﬁciency.
rAAV-IFN-c Injection Promotes Graft Rejection
We tested the hypothesis that high circulating IFN-c levels
are responsible for HSCT graft rejection, using a recombi-
nant adeno-associated viral vector encoding IFN-c (rAAV-
IFN-c). Following the intramuscular injection of 5 3 1010
rAAV-IFN-c physical particles in non-infected Ifngr1/mice,
IFN-c was secreted ectopically in the muscle and accumulated
in the serum (unpublished data), resulting on day 15 in serum
IFN-c levels ranging from 8 ng/ml to 11 ng/ml. Stable and
sustained serum IFN-c levels of 6 ng/ml to 7.5 ng/ml were
obtained 30 d after rAAV-IFN-c injection (Figure 5A),
approaching those previously quantitated after BCG infec-
tion of Ifngr1/mice. HSCT with mild conditioning was thus
performed in these mice on day 30 following rAAV-IFN-c
injection. In these conditions, HSCT graft rejection occurred
in Ifngr1/ recipients, with donor Ly5.1 lymphocytes account-
ing for only 0.46% 6 0.1% of cells (Figure 5B). In contrast,
control Ifngr1þ/þ mice given intramuscular injections of
rAAV-IFN-c displayed successful engraftment and immune
reconstitution. No detectable accumulation of IFN-c oc-
curred in Ifngr1þ/þ mice, probably because of the rapid
clearance of IFN-c by IFN-cR1-proﬁcient cells. We detected
minor increases in the serum levels of cytokines known to be
involved in the IL12/23-IFN-c circuit (IL12p40 in particular)
in both naive and infected Ifngr1/ and control Ifngr1þ/þmice,
at various stages of HSCT, with no repercussions outside this
pathway (unpublished data). These data suggest that high
circulating IFN-c levels at the time of HSCT promote graft
rejection in IFN-cR1-deﬁcient mice, even in the absence of
BCG infection.
Infected DKO Ifngr1/3 Ifng/ Mice Show No Graft
Rejection after HSCT
When infected with 106 CFU of BCG, Ifngr1/ 3 Ifng/
double knock-out (DKO) mice were unable to control the
infection and died within 12 wk of infection (unpublished
data). As expected, IFN-c was undetectable in serum (Figure
5C). Uninfected DKO mice displayed levels of chimerism
after HSCT similar to those observed in Ifngr1/ mice after
total or mild conditioning (unpublished data). DKO mice
controlled infection if HSCT with wild-type bone marrow was
carried out before BCG infection (unpublished data). We also
infected DKO mice with BCG and subjected them to HSCT,
as described above. Bone marrow reconstitution was success-
ful, and the level of chimerism obtained was similar to that in
Ifngr1þ/þ and Ifngr1/ HSCT-treated and BCG -infected mice
(Figure 5D). Successful HSCT in these recipient mice ruled
out a direct role for BCG infection, other than through IFN-c
induction, as the BCG burden in DKO mice was similar to
that in Ifngr1/mice before cell transfer. We injected 531010
physical particles of rAAV-IFN-c into DKO mice, resulting in
high serum IFN-c levels (4 ng/ml, 30 d after injection; Figure
5A). Following HSCT, engraftment was almost undetectable
in these mice, with a mean of 2.4% (6 0.5%) donor Ly5.1
lymphocytes (Figure 5B). Thus, in the absence of IFN-c,
Ifngr1/mice displayed no rejection following HSCT, despite
infection with BCG. In contrast, in the presence of high
serum levels of IFN-c, rejection occurred in these mice, even
in the absence of BCG infection. In conclusion, these data
clearly support the hypothesis that high circulating IFN-c
levels are necessary and sufﬁcient for HSCT graft rejection in
Ifngr1/ mice.
In Vivo Neutralisation of Circulating IFN-c Allows HSCT
Engraftment
High serum IFN-c concentration at the time of HSCT has a
deleterious effect on engraftment. We tried to determine
whether blood depletion of IFN-c could render HSCT of
infected Ifngr1/mice successful. A ﬁrst series of experiments
Figure 3. Rejection of the HSCT Graft in Ifngr1/ Mice Previously Infected with BCG
(A) Chimerism was determined by assessing the surface expression of Ly5.1 (donor cells) on lymphocytes, in Ifngr1/ and Ifngrþ/þmice treated by HSCT
with bone marrow from Ifngrþ/þmice, nine weeks post HSCT. Ifngr1/ and Ifngrþ/þmice were infected with BCG either before or after HSCT (five animals
per group).
(B) Bacterial loads were determined after the treatment of Ifngr1/ and Ifngrþ/þmice previously infected with BCG (three animals per group), by HSCT
with bone marrow from Ifngrþ/þ mice.
doi:10.1371/journal.pmed.0050026.g003
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was performed with anti-IFN-c antibody alone. In these
conditions IFN-c depletion was not achieved. We thus reﬁned
our protocol: animals were infected with BCG and received
four intraperitoneal doses of anti-IFN-c plus anti-IL-12
antibodies at two-day intervals, starting from day 14, before
transplantation on day 23. Another antibody injection was
administered on the day after HSCT. IFN-c depletion was
monitored by blood sampling and HSCT was performed with
mild conditioning, mimicking that used for human patients
(Figure 6A). The injection of speciﬁc antibodies into infected
Ifngr1/mice kept serum IFN-c levels below 0.5 ng/ml before
cell transfer (Figure 6B). The injection of isotype control
antibodies resulted in a serum IFN-c concentration of 1.2 ng/
ml at the time of HSCT, and ranging from 3 ng/ml to 5 ng/ml
thereafter (Figure 6C). In three of the six animals treated with
speciﬁc antibodies, serum IFN-c levels did not exceed 3 ng/ml
in the ﬁrst week after HSCT and even decreased to 0.1 ng/ml
by nine weeks post-HSCT (Figure 6B). Three other animals
behaved like the isotype control-treated group, with serum
IFN-c levels remaining high throughout the experiment.
HSCT outcome was found to be strictly correlated with serum
IFN-c concentration. Chimerism with bone marrow was
observed in the three animals in which serum IFN-c
concentrations remained low (Figure 6D, left). In contrast,
the graft was rejected in the three animals in which serum
IFN-c levels were not controlled; no donor cells were found in
such animals (Figure 6D, right). Moreover, bacterial disease
was cured in the three animals in which HSCT was successful
Figure 4. HSCT Graft Rejection Is Associated with High Serum IFN-c Levels
(A) IFN-c levels were measured over time, in the serum of Ifngr1/ and Ifngrþ/þ mice, after BCG infection (five animals per group).
(B) IFN-c levels were measured after the HSCT treatment of Ifngr1/ and Ifngrþ/þ mice with either Ifngr1/ or Ifngrþ/þ bone marrow (five animals per
group).
(C) IFN-c levels were measured in Ifngr1/ and Ifngrþ/þmice treated by HSCT with Ifngrþ/þ bone marrow, and infected with BCG before or after HSCT
(five animals per group).
(D) Northern blot analysis of Ifng and GAPDHmRNA levels in the spleens of Ifngr1/ and Ifngrþ/þmice 30 d after BCG infection (three animals per group).
Spleens were removed from animals, directly frozen in 1 ml of Trizol and stored at80 8C for further preparation. Non-infected Ifngr1/, Ifngrþ/þ, and
Ifng/ mice were used as controls (two animals per group). Means of arbitrary values obtained after scanning were calculated and normalised with
respect to the values obtained for GAPDH.
doi:10.1371/journal.pmed.0050026.g004
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Figure 5. rAAV- IFN-c Injection Promotes Graft Rejection
(A) A rAAV- IFN-c vector was designed, particles were produced and 53 1010 physical particles injected into the gastrocnemius of Ifng/mice. Serum
IFN-c levels were determined after rAAV- IFN-c injection in Ifngr1/, Ifngr1þ/þ and DKO (Ifngr1/3 Ifng/) mice (eight animals per group).
(B) Ifngr1/, Ifngrþ/þ, and DKO mice were injected with rAAV-IFN-c, and HSCT was performed with bone marrow from Ifngrþ/þ mice. The percentage
chimerism over time was monitored by determining the surface expression of Ly5.1 (donor cells) on lymphocytes (eight animals per group).
(C) Infected DKO mice showed no HSCT graft rejection. IFN-c levels were measured following BCG infection, 30 d after infection (eight animals per
group).
(D) DKO mice were infected with BCG and the percentage chimerism over time was monitored by determining the surface expression of Ly5.1 (donor
cells) on lymphocytes (eight animals per group).
doi:10.1371/journal.pmed.0050026.g005
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Figure 6. The Depletion of Circulating IFN-c Is Sufficient to Allow HSCT Engraftment
Groups of six Ifng/mice were infected with BCG and injected with a mixture of specific antibodies against IFN-c and IL-12 or with a control isotype
antibody. HSCT was carried out with bone marrow from Ifngrþ/þmice and serum IFN-c levels were monitored over time (A). Data are plotted individually
for each animal treated with specific antibodies (B) and control isotype antibodies (C). The percentage chimerism was evaluated and representative
FACS analyses are shown for engraftment (D), corresponding to three animals with low serum levels of IFN-c (left) and rejection, corresponding to six
animals with high serum levels of IFN-c (right).
doi:10.1371/journal.pmed.0050026.g006
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(unpublished data). Our data therefore demonstrate that
efﬁcient IFN-c depletion by antibody administration im-
proves engraftment in Ifngr1/ mice.
Discussion
We have shown that the surface expression of functional
IFN-cR1 in the haematopoietic compartment alone—actually
in only about half of that compartment—is sufﬁcient to protect
mice against BCG infection. Similarly, Yap and Sher previously
showed that IFN-cR1 expression in the haematopoietic
compartment was sufﬁcient to restore resistance to the
intracellular macrophage-tropic bacterium Listeria monocyto-
genes in IFN-cR1-deﬁcient mice [37]. However, they also showed
that IFN-cR1 expression on both haematopoietic and non-
haematopoietic cells was required to confer resistance to the
macrophage-tropic intracellular protozoon Toxoplasma gondii
[37]. Consistent with these ﬁndings, Dal Canto and Virgin
showed that IFN-c acted directly on both haematopoietic and
non-haematopoietic cells during infection with the medial
smooth muscle murine tropic c-herpesvirus-68 [38]. Thus,
despite the almost ubiquitous expression of IFN-cR1 on both
haematopoietic and non-haematopoietic cells [39–41], BCG
infection can be controlled—as attested by bacterial killing,
granuloma structure, and animal survival—by the restricted
action of IFN-c on the haematopoietic compartment. Results
obtained in our murine model are consistent with data from
patients with complete IFN-cR1 deﬁciency undergoing HSCT
[12–15] and demonstrate that susceptibility to BCG, and by
extension to other mycobacteria, is a haematopoietic disease in
persons with IFN-cR1 deﬁciency. In mice and humans, the
extra-haematopoietic expression of IFN-cR1 is redundant for
anti-mycobacterial protective immunity.
Likewise, in both mice and humans, the rate of HSCT graft
rejection is also very high in individuals lacking IFN-cR1 and
infected with mycobacteria. Moreover, high levels of circulat-
ing IFN-c account for this high rate of rejection. Ifngr1/
mice reject even syngeneic grafts from IFN-cR1-expressing
mice, in all conditions resulting in high serum IFN-c levels,
including mycobacterial disease and intramuscular injections
of rAAV-IFN-c. We have shown that IFN-c is necessary and
sufﬁcient for HSCT graft rejection. IFN-c has already been
shown to have a direct inhibitory effect on myeloid,
erythroid, megakaryocyte, and multipotent colony formation
in human cultures in vitro [42,43]. Moreover, in long-term
bone marrow cultures—the in vitro assay best mimicking the
complex interactions occurring in intact bone marrow—
Selleri et al. showed that local IFN-c overproduction by
stromal cells inhibits haematopoiesis [44]. Two mechanisms
seem to be responsible for the anti-haematopoietic effect of
IFN-c: the direct killing of stem cells and the inhibition of cell
cycling [44,45]. The exposure of primitive human haemato-
poietic stem cells to IFN-c in vitro increases Fas antigen
expression, thereby rendering the cells more susceptible to
apoptosis [46]. In vivo studies in mouse models have
conﬁrmed these results. Transgenic mice expressing multiple
copies of the IFN-c gene, leading to high levels of IFN-c
production in the bone marrow and thymus, display
hypocellularity, and multiple alterations of the immune
system [47]. There is also a strong correlation between the
degree of heamatopoietic suppression and the level of IFN-c
in vitro [48,49]. Altogether, these observations most likely
account for the detrimental effects of high levels of
circulating IFN-c in IFN-cR1-deﬁcient mice and humans
undergoing HSCT.
The negative impact of high IFN-c levels, leading to HSCT
graft rejection, has important clinical implications for the
treatment of people with complete IFN-cR1 deﬁciency.
Attempts could be made to decrease levels of circulating
IFN-c before HSCT. As recently shown, antibiotics may not
eradicate M. fortuitum infection, but they do markedly
decrease serum IFN-c concentration before HSCT [15].
Prolonged treatment with multiple anti-mycobacterial anti-
biotics is therefore required, but is unlikely to decrease IFN-c
levels sufﬁciently and is unlikely to cure most of the patients
[7]. In this study, we explored the use of speciﬁc antibodies to
deplete the blood of IFN-c. As anti-IFN-c antibodies alone
were not sufﬁcient for IFN-c depletion, we also used anti-IL-
12p40 antibodies [50] to achieve efﬁcient depletion of IFN-c
in the serum. Infected IFN-cR1-deﬁcient mice treated in this
way displayed engraftment and control of the mycobacterial
infection after HSCT. Anti-IL-12 and anti-IFN-c antibodies
have already been used to treat human immune diseases, such
as psoriasis and Crohn’s disease [51–53]. The clinical use of
these antibodies before HSCT is therefore feasible in IFN-
cR1-deﬁcient patients. Our study paves the way for improve-
ments in transplantation conditions in people with IFN-cR1
deﬁciency, or with other diseases associated with elevated
levels of circulating IFN-c, such as IFN-cR2 deﬁciency [54].
We can also speculate that the use of such antibodies may also
reduce the risks of HSCT rejection, improving engraftment,
in other settings, such as HSCT from a haplo-identical or
matched unrelated donor [16,55]. Although we did not
observe any detrimental effect of rAAV-IFN-c an HLA-
identical setting in our mouse model, the depletion of IFN-c
in patients with conditions associated with high rates of graft
rejection, such as HLA-II deﬁciency [56], or in other patients
undergoing haplo-identical transplantations, might be bene-
ﬁcial. Further experimental studies in mice should be done
before the corresponding clinical trials can be undertaken.
Acknowledgments
We would like to thank Anne-Marie Douar from Genethon, Evry for
rAAV production. We also thank Joachim Roesler for personal
communications concerning patients and Alain Fischer for initially
suggesting the potential role of IFN-c in graft rejection. We would
like to thank all members of the Laboratory of Human Genetics of
Infectious Diseases for helpful discussions.
Author contributions.MR, CS, JLG, and JLC designed the study and
contributed to the writing. MR and CS performed the experiments.
MR, CS, GV, LR, JFE, HD, JLG, and JLC analyzed the data. LR
provided the antibody and contributed to the design of the cytokine
neutralisation experiment. JFE did the histology analysis.
References
1. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA (2005)
Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human
genes and genetic disorders. Nucleic Acids Res 33: D514–D517.
2. Casanova JL, Abel L (2002) Genetic dissection of immunity to mycobac-
teria: the human model. Annu Rev Immunol 20: 581–620.
3. Filipe-Santos O, Bustamante J, Chapgier A, Vogt G, de Beaucoudrey L, et al.
(2006) Inborn errors of IL-12/23- and IFN-gamma-mediated immunity:
molecular, cellular, and clinical features. Semin Immunol 18: 347–361.
4. Jouanguy E, Altare F, Lamhamedi S, Revy P, Emile JF, et al. (1996)
Interferon-gamma-receptor deﬁciency in an infant with fatal bacille
Calmette-Guerin infection. N Engl J Med 335: 1956–1961.
5. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, et al.
(1996) A mutation in the interferon-gamma-receptor gene and suscepti-
bility to mycobacterial infection. N Engl J Med 335: 1941–1949.
6. Jouanguy E, Dupuis S, Pallier A, Dofﬁnger R, Fondaneche MC, et al. (2000)
PLoS Medicine | www.plosmedicine.org January 2008 | Volume 5 | Issue 1 | e260161
IFN-c Mediates HSCT Rejection
In a novel form of IFN-gamma receptor 1 deﬁciency, cell surface receptors
fail to bind IFN-gamma. J Clin Invest 105: 1429–1436.
7. Dorman SE, Picard C, Lammas D, Heyne K, van Dissel JT, et al. (2004)
Clinical features of dominant and recessive interferon gamma receptor 1
deﬁciencies. Lancet 364: 2113–2121.
8. Alcais A, Fieschi C, Abel L, Casanova JL (2005) Tuberculosis in children and
adults: two distincts genetic diseases. J Exp Med 202: 1617–1621.
9. MacLennan C, Fieschi C, Lammas D, Picard C, Dorman SE, et al. (2004)
Interleukin (IL)-12 and IL-23 are key cytokines for immunity against
Salmonella in humans. J Infect Dis 190: 1755–1757.
10. Roesler J, Koﬁnk B, Wendisch J, Heyden S, Paul D, et al. (1999) Listeria
monocytogenes and recurrent mycobacterial infections in a child with
complete interferon-gamma-receptor (IFNgammaR1) deﬁciency: muta-
tional analysis and evaluation of therapeutic options. Exp Hematol 27:
1368–1374.
11. Emile JF, Patey N, Altare F, Lamhamedi S, Jouanguy E, et al. (1997)
Correlation of granuloma structure with clinical outcome deﬁnes two types
of idiopathic disseminated BCG infection. J Pathol 181: 25–30.
12. Reuter U, Roesler J, Thiede C, Schulz A, Classen CF, et al. (2002) Correction
of complete interferon-gamma receptor 1 deﬁciency by bone marrow
transplantation. Blood 100: 4234–4235.
13. Roesler J, Horwitz ME, Picard C, Bordigoni P, Davies G, et al. (2004)
Hematopoietic stem cell transplantation for complete IFN-gamma recep-
tor 1 deﬁciency: a multi-institutional survey. J Pediatr 145: 806–812.
14. Horwitz ME, Uzel G, Linton GF, Miller JA, Brown MR, et al. (2003)
Persistent Mycobacterium avium infection following nonmyeloablative
allogeneic peripheral blood stem cell transplantation for interferon-
gamma receptor-1 deﬁciency. Blood 102: 2692–2694.
15. Chantrain CF, Bruwier A, Brichard B, Largent V, Chapgier A, et al. (2006)
Successful hematopoietic stem cell transplantation in a child with active
disseminated Mycobacterium fortuitum infection and interferon-gamma
receptor 1 deﬁciency. Bone Marrow Transplant 38: 75–76.
16. Antoine C, Muller S, Cant A, Cavazzana-Calvo M, Veys P, et al. (2003) Long-
term survival and transplantation of haemopoietic stem cells for
immunodeﬁciencies: report of the European experience 1968–99. Lancet
361: 553–560.
17. Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, et al. (1993)
Immune response in mice that lack the interferon-gamma receptor.
Science 259: 1742–1745.
18. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, et al. (1993)
Multiple defects of immune cell function in mice with disrupted
interferon-gamma genes. Science 259: 1739–1742.
19. Swihart K, Fruth U, Messmer N, Hug K, Behin R, et al. (1995) Mice from a
genetically resistant background lacking the interferon gamma receptor
are susceptible to infection with Leishmania major but mount a polarized
T helper cell 1-type CD4þ T cell response. J Exp Med 181: 961–971.
20. Zhao YX, Tarkowski A (1995) Impact of interferon-gamma receptor
deﬁciency on experimental Staphylococcus aureus septicemia and arthritis.
J Immunol 155: 5736–5742.
21. Mastroeni P, Clare S, Khan S, Harrison JA, Hormaeche CE, et al. (1999)
Interleukin 18 contributes to host resistance and gamma interferon
production in mice infected with virulent Salmonella typhimurium. Infect
Immun 67: 478–483.
22. Rijneveld AW, Lauw FN, Schultz MJ, Florquin S, Te Velde AA, et al. (2002)
The role of interferon-gamma in murine pneumococcal pneumonia. J
Infect Dis 185: 91–97.
23. Cantin E, Tanamachi B, Openshaw H (1999) Role for gamma interferon in
control of herpes simplex virus type 1 reactivation. J Virol 73: 3418–3423.
24. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, et al. (1993) An
essential role for interferon gamma in resistance to Mycobacterium
tuberculosis infection. J Exp Med 178: 2249–2254.
25. Garcia I, Miyazaki Y, Marchal G, Lesslauer W, Vassalli P (1997) High
sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to
mycobacterial infections: synergistic action of TNF and IFN-gamma in the
differentiation of protective granulomas. Eur J Immunol 27: 3182–3190.
26. Doherty TM, Sher A (1997) Defects in cell-mediated immunity affect
chronic, but not innate, resistance of mice to Mycobacterium avium
infection. J Immunol 158: 4822–4831.
27. Kamijo R, Le J, Shapiro D, Havell EA, Huang S, et al. (1993) Mice that lack
the interferon-gamma receptor have profoundly altered responses to
infection with Bacillus Calmette-Guerin and subsequent challenge with
lipopolysaccharide. J Exp Med 178: 1435–1440.
28. Gheorghui M, Augier J, Lagrange P (1983) Maintenance and control of the
French BCG strain 1173-P2 (primary and secondary seeding lots). Bull Inst
Pasteur 81: 281–288.
29. Ehlers S, Richter E (2001) Differential requirement for interferon-gamma
to restrict the growth of or eliminate some recently identiﬁed species of
nontuberculous mycobacteria in vivo. Clin Exp Immunol 124: 229–238.
30. Douar AM, Poulard K, Stockholm D, Danos O (2001) Intracellular
trafﬁcking of adeno-associated virus vectors: routing to the late endosomal
compartment and proteasome degradation. J Virol 75: 1824–1833.
31. Snyder RO, Spratt SK, Lagarde C, Bohl D, Kaspar B, et al. (1997) Efﬁcient
and stable adeno-associated virus-mediated transduction in the skeletal
muscle of adult immunocompetent mice. Hum Gene Ther 8: 1891–1900.
32. Cherwinski HM, Schumacher JH, Brown KD, Mosmann TR (1987) Two
types of mouse helper T cell clone. III. Further differences in lymphokine
synthesis between Th1 and Th2 clones revealed by RNA hybridization,
functionally monospeciﬁc bioassays, and monoclonal antibodies. J Exp Med
166: 1229–1244.
33. Wysocka M, Kubin M, Vieira LQ, Ozmen L, Garotta G, et al. (1995)
Interleukin-12 is required for interferon-gamma production and lethality
in lipopolysaccharide-induced shock in mice. Eur J Immunol 25: 672–676
34. Belnoue E, Costa FT, Frankenberg T, Vigario AM, Voza T, et al. (2004)
Protective T cell immunity against malaria liver stage after vaccination with
live sporozoites under chloroquine treatment. J Immunol 172: 2487–2495.
35. Fieschi C, Dupuis S, Picard C, Smith CI, Holland SM, et al. (2001) High
levels of interferon gamma in the plasma of children with complete
interferon gamma receptor deﬁciency. Pediatrics 107: E48.
36. Kamijo R, Gerecitano J, Shapiro D, Green SJ, Aguet M, et al. (1995)
Generation of nitric oxide and clearance of interferon-gamma after BCG
infection are impaired in mice that lack the interferon-gamma receptor. J
Inﬂamm 46: 23–31.
37. Yap GS, Sher A (1999) Effector cells of both nonhemopoietic and
hemopoietic origin are required for interferon (IFN)-gamma- and tumor
necrosis factor (TNF)-alpha-dependent host resistance to the intracellular
pathogen, Toxoplasma gondii. J Exp Med 189: 1083–1092.
38. Dal Canto AJ, Swanson PE, O’Guin AK, Speck SH, Virgin HW (2001) IFN-
gamma action in the media of the great elastic arteries, a novel
immunoprivileged site. J Clin Invest 107: R15–22.
39. Celada A (1988) The interferon gamma receptor. Lymphokine Res 7: 61–73.
40. Valente G, Ozmen L, Novelli F, Geuna M, Palestro G, et al. (1992)
Distribution of interferon-gamma receptor in human tissues. Eur J
Immunol 22: 2403–2412.
41. Farrar MA, Schreiber RD (1993) The molecular cell biology of interferon-
gamma and its receptor. Annu Rev Immunol 11: 571–611.
42. Broxmeyer HE, Williams DE, Lu L, Cooper S, Anderson SL, et al. (1986) The
suppressive inﬂuences of human tumor necrosis factors on bone marrow
hematopoietic progenitor cells from normal donors and patients with
leukemia: synergism of tumor necrosis factor and interferon-gamma. J
Immunol 136: 4487–4495.
43. Raefsky EL, Platanias LC, Zoumbos NC, Young NS (1985) Studies of
interferon as a regulator of hematopoietic cell proliferation. J Immunol
135: 2507–2512.
44. Selleri C, Maciejewski JP, Sato T, Young NS (1996) Interferon-gamma
constitutively expressed in the stromal microenvironment of human
marrow cultures mediates potent hematopoietic inhibition. Blood 87:
4149–4157.
45. Selleri C, Sato T, Anderson S, Young NS, Maciejewski JP (1995) Interferon-
gamma and tumor necrosis factor-alpha suppress both early and late stages
of heamatopoiesis and induces programmed cell death. J Cell Physiol 165:
538–546.
46. Maciejewski JP, Selleri C, Anderson S, Young NS (1995) Fas antigen
expression on CD34þhuman marrow cells is induced by interferon-gamma
and tumor necrosis factor-alpha and potentiates cytokine-mediated
hematopoietic suppression in vitro. Blood 85: 3183–3190.
47. Young HA, Klinman DM, Reynolds DA, Grzegorzewski KJ, Nii A, et al.
(1997) Bone marrow and thymus expression of interferon-gamma results in
severe B-cell lineage reduction, T-cell lineage alterations, and hemato-
poietic progenitor deﬁciencies. Blood 89: 583–595.
48. Zoumbos NC, Djeu JY, Young NS (1984) Interferon is the suppressor of
hematopoiesis generated by stimulated lymphocytes in vitro. J Immunol
133: 769–774.
49. Angulo I, Rodriguez R, Garcia B, Medina M, Navarro J, et al. (1995)
Involvement of nitric oxide in bone marrow-derived natural suppressor
activity; its dependence on IFNg. J Immunol 155: 15–26.
50. Toichi E, Torres G, McCormick TS, Chang T, Mascelli MA, et al. (2006) An
anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and
IL-12/23 in psoriais. J Immunol 177: 4917–4926.
51. Kaufmann CL, Aria N, Toichi E, McCormick TS, Cooper KD, et al. (2004) A
phase I study evaluating the safety, pharmacokinetics, and clinical response
of a human IL-12p40 antibody in subjects with plaque psoriasis. J Invest
Dermatol 123: 1037–1044.
52. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, et al. (2004) Anti-
interleukin-12 antibody for active Crohn’s disease. N Engl J Med 351: 2069–
2079.
53. Skurkovich B, Skurkovich S (2003) Anti-interferon-gamma antibodies in
the treatment of autoimmune diseases. Curr Opin Mol Ther 5: 52–57.
54. Vogt G, Chapgier A, Yang K, Chuzhanova N, Feinberg J, et al. (2005) Gains
of glycosylation comprise an unexpectedly large group of pathogenic
mutations. Nat Genet 37: 692–700.
55. Ruggeri L, Aversa F, Martelli MF, Velardi A (2006) Allogenic hematopoietic
transplantation and natural killer cell recognition of missing self.
Immunological Reviews 214: 202–218.
56. Renella R, Picard C, Neven B, Ouache´e-Chardin M, Casanova JL, et al.
(2006) Human leucocyte antigen-identical haematopoietic stem cell trans-
plantation in major histocompatiblity complex class II immunodeﬁciency:
reduced survival correlates with an increased incidence of acute graft-
versus-host disease and pre-existing viral infections. Br J. Haematol 136:
510–516.
PLoS Medicine | www.plosmedicine.org January 2008 | Volume 5 | Issue 1 | e260162
IFN-c Mediates HSCT Rejection
Editors’ Summary
Background. Normally, the body’s immune system efficiently recognizes
and kills bacteria and viruses, but in some rare inherited disorders
(‘‘primary immunodeficiencies’’) part of the immune system works
poorly or is missing. This leaves affected individuals susceptible to
infections. People with one of these disorders—interferon-gamma
receptor 1 (IFN- cR1) deficiency—are very susceptible to infections with
mycobacteria. Except for Mycobacterium tuberculosis and M. leprae
(which cause tuberculosis and leprosy, respectively), mycobacteria rarely
cause human disease. However, most people with IFN-cR1 deficiency die
during childhood from multiple, widespread mycobacterial infections,
because IFN-cR1 deficiency disables a specific part of their immune
system. When most bacteria enter the body, immune system cells called
macrophages engulf and kill them, but mycobacteria actually multiply
inside macrophages. This infection stimulates lymphocytes and other
immune system cells to release IFN-c, which binds to IFN-cR1 on
uninfected macrophages, activates them, and recruits them to the
infection site. Here, they form a ‘‘granuloma,’’ a mass of macrophages
and activated lymphocytes that ‘‘walls off’’ the infection. Granuloma
formation does not occur in patients with IFN-cR1 deficiency, so
mycobacteria (including the usually benign tuberculosis vaccination
strain M. bovis BCG) spread throughout the body with disastrous
consequences.
Why Was This Study Done? The only effective treatment for patients
with IFN-cR1 deficiency is hematopoietic stem cell transplantation
(HSCT). HSCs are the source of all the immune system cells, so
transplantation of HSCs from a donor with a normal IFNGR1 gene can
provide a patient who has IFN-cR1 deficiency with a new immune system
that can combat mycobacterial infections. Unfortunately, in this
particular immune deficiency, the new HSCs cannot engraft, even when
the patient’s own immune system is disabled before HSCT by intensive
chemotherapy, and when the donor cells come from a close relative and
are a good immunological match. In this study, the researchers have
investigated why rejection is so common in IFN-cR1 deficiency using a
mouse strain called C57BL/6 Ifngr1/—C57BL/6 denotes the genetic
background of these mice and Ifngr1/ indicates that, like human
patients, these mice make no IFN-cR1.
What Did the Researchers Do and Find? Ifngr1/mice, the researchers
report, cannot control M. bovis BCG infections and do not form mature
granulomas just like human patients with IFN-cR1 deficiency. Wild-type
C57BL/6 (Ifngr1þ/þ) mice, however, rapidly control M. bovis BCG infections
and form mature granulomas. Ifngr1þ/þ HSC transplanted into mycobac-
teria-free Ifngr1/ mice survived well and protected the mice against
later mycobacterial challenge but Ifngr1/ mice infected with M. bovis
BCG before HSCT rejected the transplanted HSCs. Mycobacteria-infected
Ifngr1/ mice and human patients with IFN-cR1 deficiency have blood
high levels of IFN-c. Could this be responsible for HSCT rejection? To find
out, the researchers expressed IFN-c in uninfected Ifngr1/ mice before
HSCT. As in infected mice, these grafts failed. Conversely, transplanted
HSCs survived when transplanted into Ifngr1/ mice that had been
genetically altered to express no IFN-c, even when these mice were
infected with M. bovis BCG before transplantation. Finally, when the
researchers used antibodies (proteins made by the immune system that
recognize specific molecules) to remove circulating IFN-c from infected
Ifngr1/ mice, HSCT worked well in the animals with the lowest IFN-c
levels.
What Do These Findings Mean? These findings indicate that in a
mouse model of IFN-cR1 deficiency, high circulating IFN-c concen-
trations drive the rejection of transplanted HSCs and prevent the
development of antimycobacterial immunity, probably by directly killing
the transplanted cells and/or stopping them multiplying. They also
suggest how HSCT could be improved in patients with IFN-cR1
deficiency although, as with all animal studies, the situation in people
might turn out to be very different. Importantly, antibodies that reduce
circulating IFN-c are already being used to treat other human immune
diseases, so the clinical use of these antibodies in patients with IFN-c
deficiency before HSCT is feasible. Finally, the researchers speculate that
the use of IFN-c–depleting antibodies might be beneficial in other
situations where HSCT often fails such as when a close relative is not
available as a donor. However, this possibility will need to be thoroughly
tested in mice before human clinical trials can be started.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050026.
 General information about primary immunodeficiencies is available
from the US National Institute of Child Health and Human Develop-
ment
 Online Mendelian Inheritance in Man (OMIM) provides information
about familial predisposition to mycobacterial disease
 Wikipedia has pages on hematopoietic stem cell transplantation and
on interferon-c (note that Wikipedia is a free online encyclopedia that
anyone can edit; available in several languages)
 The Human Genetics of Infectious Diseases Lab focuses on the genetic
basis of predicposition or resistance to infectious diseases in humans
PLoS Medicine | www.plosmedicine.org January 2008 | Volume 5 | Issue 1 | e260163
IFN-c Mediates HSCT Rejection
